公开(公告)号：US20220118068A1

公开(公告)日：2022-04-21

申请号：US17515001

申请日：2021-10-29

申请人： PEMI31 Therapeutics Inc.

发明人： Edward R.M. O'Brien ,  Chunhua Shi ,  Yong-Xiang Chen

IPC分类号： A61K39/00 ,  C07K16/18 ,  G01N33/543 ,  A61K39/39 ,  C07K14/47 ,  A61K38/17 ,  C12N9/58 ,  A61P3/06 ,  A61K39/395

摘要： This disclosure pertains to compositions and methods for reducing serum cholesterol in mammalian subjects. The exemplary compositions comprise mixtures of HSP27 protein or fragments thereof, a HSP25 protein or fraction thereof, a recombinant rHSP25 peptide, or a recombinant HSP27 peptide in a mixture with an adjuvant. The compositions may optionally comprise anti-HSP27 antibody. The methods for reducing serum cholesterol in mammalian subjects relate to the use of the compositions to increase the subjects' levels of serum HSP27 and/or anti-HSP27 antibodies.

公开(公告)号：US11439696B2

公开(公告)日：2022-09-13

申请号：US15756282

申请日：2016-08-29

申请人： PEMI31 Therapeutics Inc.

发明人： Edward R. M. O'Brien ,  Chunhua Shi ,  Yong-Xiang Chen

IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/18 ,  G01N33/543 ,  A61K39/39 ,  C07K14/47 ,  A61K38/17 ,  C12N9/58 ,  A61P3/06

摘要： The patent application pertains to compositions and methods for reducing Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) expression and for reducing serum cholesterol in mammalian subjects. The exemplary compositions comprise heat0 shock protein HSP27 or fragments thereof and/or a HSP25, or fragments thereof in a mixture with an adjuvant. The compositions may optionally comprise anti-HSP27 antibody. The method for reducing serum cholesterol relate to the use of the compositions to increase the subject's levels of serum HSP27 and/or anti-HSP27 antibodies.

公开(公告)号：US12005101B2

公开(公告)日：2024-06-11

申请号：US17515001

申请日：2021-10-29

申请人： PEMI31 Therapeutics Inc.

发明人： Edward R. M. O'Brien ,  Chunhua Shi ,  Yong-Xiang Chen

IPC分类号： A61K39/00 ,  A61K38/17 ,  A61K39/39 ,  A61K39/395 ,  A61P3/06 ,  C07K14/47 ,  C07K16/18 ,  C12N9/58 ,  G01N33/543

CPC分类号： A61K39/0005 ,  A61K38/1709 ,  A61K39/39 ,  A61K39/3955 ,  A61P3/06 ,  C07K14/47 ,  C07K14/4703 ,  C07K16/18 ,  C12N9/58 ,  G01N33/54326 ,  A61K39/395 ,  A61K2039/55505 ,  A61K2039/55566 ,  G01N2333/4703

摘要： This disclosure pertains to compositions and methods for reducing serum cholesterol in mammalian subjects. The exemplary compositions comprise mixtures of HSP27 protein or fragments thereof, a HSP25 protein or fraction thereof, a recombinant rHSP25 peptide, or a recombinant HSP27 peptide in a mixture with an adjuvant. The compositions may optionally comprise anti-HSP27 antibody. The methods for reducing serum cholesterol in mammalian subjects relate to the use of the compositions to increase the subjects' levels of serum HSP27 and/or anti-HSP27 antibodies.

公开(公告)号：US20230210943A1

公开(公告)日：2023-07-06

申请号：US17927728

申请日：2021-05-28

申请人： PEMI31 THERAPEUTICS INC.

发明人： Edward Redmond O'BRIEN

IPC分类号： A61K38/17 ,  C07K16/18 ,  A61P1/16

CPC分类号： A61K38/1709 ,  C07K16/18 ,  A61P1/16

摘要： Disclosed are methods for the treatment of non-fatty liver disease (NAFLD). The methods involve the administration to a subject in need thereof of a pharmaceutical formulation comprising an HSP27 polypeptide or immunologically equivalent portion thereof, or an anti-HSP27 antibody or a functional anti-HSP27 antibody fragment, or a mixture of an HSP27 polypeptide or immunologically equivalent portion thereof, and an anti-HSP27 antibody or a functional anti-HSP27 antibody fragment.